Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Total Non-Current Liabilities: 2023-2025

  • Zenas BioPharma's Total Non-Current Liabilities was N/A to $73.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.2 million, marking a year-over-year change of. This contributed to the annual value of $218,000 for FY2024, which is 99.07% down from last year.
  • Latest data reveals that Zenas BioPharma reported Total Non-Current Liabilities of $73.2 million as of Q3 2025, which was up 33,463.76% from $218,000 recorded in Q4 2024.
  • In the past 5 years, Zenas BioPharma's Total Non-Current Liabilities registered a high of $73.2 million during Q3 2025, and its lowest value of $218,000 during Q4 2024.
  • In the last 3 years, Zenas BioPharma's Total Non-Current Liabilities had a median value of $23.5 million in 2023 and averaged $32.3 million.
  • Data for Zenas BioPharma's Total Non-Current Liabilities shows a maximum YoY tumbled of 99.07% (in 2024) over the last 5 years.
  • Over the past 3 years, Zenas BioPharma's Total Non-Current Liabilities (Quarterly) stood at $23.5 million in 2023, then tumbled by 99.07% to $218,000 in 2024, then reached $73.2 million in 2025.
  • Its Total Non-Current Liabilities stands at $73.2 million for Q3 2025, versus $218,000 for Q4 2024 and $23.5 million for Q4 2023.